细胞角蛋白19基因扩增及过度表达的研究  

Expression of CK19 and its significance in breast cancer

作　　者：邓君[1] 黄文方[1] 饶绍琴[1] 

机构地区：[1]四川省医学科学院四川省人民医院检验科,四川成都610072

出　　处：《现代肿瘤医学》2009年第2期243-245,共3页Journal of Modern Oncology

基　　金：四川省青年科技基金资助项目(编号:2007-05-345)

摘　　要：目的:建立荧光定量聚合酶链反应(FQ-PCR)法检测CK19基因表达水平,探讨其在乳腺癌诊断和治疗监测中的应用。方法:建立FQ-PCR法,并以β2-微球蛋白为内对照测定30名健康女性体检者、30例良性乳腺疾病患者和91例乳腺癌患者外周血中CK19的表达。结果:CK19表达水平在正常对照组和良性乳腺疾病组间差异无显著性意义(P>0.05),乳腺癌组均高于前两组(P<0.05),β2-微球蛋白在三组间差异无显著性意义(P>0.05)。91例乳腺癌患者阳性率为49.5%,良性乳腺疾病组为0。CK19表达与患者年龄和肿瘤大小和类型无关(P>0.05),与乳腺癌临床分期、组织学分级以及腋淋巴结转移相关(P<0.05)。结论:FQ-PCR技术是高度灵敏、高度特异的快速定量检测CK19方法,可有效监测乳腺癌的诊断、疗效、转移和预后。Objective：To evaluate the clinical application of fluorescent quantification polymerase chain reaction （FQ- PCR） to detect CK19 in the breast cancer. Methods： CK19 in 30 health women, 30 patients with benign breast disease and 91 patients with breast cancer were detected by FQ - PCR. β2 - microglobin was used as internal control. Results： There were no significant difference in CK19/β2 -microglobin between normal controls and benign breast disease group（P 〉 0.05 ）. CK19/β2- microglobin in breast cancer group were higher than those in the other groups（ P 〈 0.05 ）. There were no difference in β2 -microglobin among three groups（ P 〉 0.05 ）. The positive ratio of breast cancer and benign disease were 49.5 and 0 percent respectively. No significant association of CK19 expression among age and tumor size and type was noted （ P 〉 0.05 ） , but its expression in breast cancer was correlated with clinical stage, histological grade and axillary metastatic lymph node （P 〈 0.05 ）. Conclusion： FQ -PCR is a rapid and sensitive and specific method for quantitating CK19. It also gives objective evidence to the diagnosis, therapy, metastasis of breast cancer.

关 键 词：荧光定量聚合酶链反应 CK19 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]